ok lets talk business. assuming the 85% is achieved (a big IF). a percentage of failures will seek retreatment, and i would presume most would need an agent with novel MOA given resistance issues. it seems reasonable to think many of these failures will then go on an INF-based regimen. even if only a third of the 15% then go on to INF - that is 5% of patients seeking treatment will ultimately see INF. that could be 5% of several million...now how does that compare with the revenue potential for the 4th protease inhibitor introduced that may or may not have advantages over its predecessors?
News 
Market Data 
Discover 
AI
